X


See our webpage about the GA-map® product platform

 

Visit page
Skip to content
Genetic Analysis
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us

Press Releases

Genetic Analysis AS (GEAN): Registration of share capital increase

2021-09-24

Genetic Analysis AS (GEAN): Minutes from the Extraordinary General Meeting

2021-09-222021-09-20

Genetic Analysis AS (GEAN): Mandatory notification of trade

2021-09-242021-09-15

Genetic Analysis AS (GEAN) : IPO prior to listing was significantly oversubscribed

2021-09-222021-09-15

Genetic Analysis AS (GEAN): Notice of Extraordinary General Meeting

2021-09-222021-09-13

The subscription period begins in Genetic Analysis AS issue of units prior to planned listing on Spotlight Stock Market

2021-09-222021-08-30

Genetic Analysis AS receives preliminary approval for listing and publishes prospectus in connection with planned IPO

2021-09-222021-08-24

Genetic Analysis AS releases Interim report January – June 2021

2021-09-222021-08-20

Genetic Analysis Co-develops HumGut – The world’s first complete database of reference genomes

2021-09-242021-08-05

Eagle Biosciences Announces Agreement with Genetic Analysis AS for Distribution in North America

2021-09-242021-06-16
Post navigation
Older posts
Newer posts
← Previous Page1 … Page12 Page13 Page14 Next →

Genetic Analysis AS is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Contact

Phone: +47 48 32 16 10
E-mail: info@genetic-analysis.com
Address: Genetic Analysis AS, Ulvenveien 80B
0581 Oslo, Norway

Open Google Maps
Connect

LinkedIn

Facebook

Twitter

Navigate

Contact Us

Terms of Use

Privacy Policy

© 2023 Genetic Analysis

  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us